Halozyme Defends Drug Delivery IP In Battle With Merck
Halozyme has denied claims that its patent for an under-the-skin drug delivery system should be nixed, asking a London court to stop Merck Sharp & Dohme from launching a new cancer...To view the full article, register now.
Already a subscriber? Click here to view full article